Tumor immunotargeting using innovative radionuclides

This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative r...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2015-02, Vol.16 (2), p.3932-3954
Main Authors: Kraeber-Bodéré, Françoise, Rousseau, Caroline, Bodet-Milin, Caroline, Mathieu, Cédric, Guérard, François, Frampas, Eric, Carlier, Thomas, Chouin, Nicolas, Haddad, Ferid, Chatal, Jean-François, Faivre-Chauvet, Alain, Chérel, Michel, Barbet, Jacques
Format: Article
Language:English
Subjects:
alpha particle-emitting radionuclides
alpha-immunotherapy
Antibodies, Monoclonal - administration & dosage
Cancer
Diagnostic Imaging
Humans
immuno-PET
Immunoglobulins
innovative radionuclides
Life Sciences
Medical imaging
Neoplasms - diagnostic imaging
Neoplasms - therapy
radioimmunotherapy
Radioimmunotherapy - methods
Radioisotopes - administration & dosage
Radionuclide Imaging
Review
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms16023932